- Home
- MSBI vs PROK Comparison
MSBI vs PROK Comparison
Compare MSBI & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSBI
- PROK
- Stock Information
- Founded
- MSBI 1881
- PROK 2015
- Country
- MSBI United States
- PROK United States
- Employees
- MSBI N/A
- PROK N/A
- Industry
- MSBI Major Banks
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MSBI Finance
- PROK Health Care
- Exchange
- MSBI Nasdaq
- PROK Nasdaq
- Market Cap
- MSBI 378.1M
- PROK 417.1M
- IPO Year
- MSBI 2016
- PROK N/A
- Fundamental
- Price
- MSBI $16.31
- PROK $3.16
- Analyst Decision
- MSBI Hold
- PROK Strong Buy
- Analyst Count
- MSBI 3
- PROK 4
- Target Price
- MSBI $20.67
- PROK $6.25
- AVG Volume (30 Days)
- MSBI 137.1K
- PROK 2.2M
- Earning Date
- MSBI 10-30-2025
- PROK 11-11-2025
- Dividend Yield
- MSBI 7.59%
- PROK N/A
- EPS Growth
- MSBI N/A
- PROK N/A
- EPS
- MSBI N/A
- PROK N/A
- Revenue
- MSBI $224,320,000.00
- PROK $527,000.00
- Revenue This Year
- MSBI $27.04
- PROK $471.74
- Revenue Next Year
- MSBI N/A
- PROK N/A
- P/E Ratio
- MSBI N/A
- PROK N/A
- Revenue Growth
- MSBI N/A
- PROK N/A
- 52 Week Low
- MSBI $14.79
- PROK $0.46
- 52 Week High
- MSBI $28.08
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- MSBI 43.58
- PROK 57.00
- Support Level
- MSBI $15.45
- PROK $2.91
- Resistance Level
- MSBI $16.76
- PROK $3.45
- Average True Range (ATR)
- MSBI 0.48
- PROK 0.27
- MACD
- MSBI 0.05
- PROK 0.01
- Stochastic Oscillator
- MSBI 51.30
- PROK 57.43
About MSBI Midland States Bancorp Inc.
Midland States Bancorp Inc is a diversified financial holding company. The company provides a full range of commercial and consumer banking products and services, business equipment financing, merchant credit card services, trust and investment management, and insurance and financial planning services. The Banking segment, which generates the majority of the revenue, provides financial products and services to consumers and businesses, including commercial, commercial real estate, mortgage, and other consumer loan products; commercial equipment financing, etc. The Wealth Management segment consists of trust and fiduciary services, brokerage, and retirement planning services. The Corporate segment includes the holding company's financing and investment activities, administrative expenses.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.